Please login to the form below

Not currently logged in
Email:
Password:

UCB launches epilepsy campaign

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day.

The annual event is co-ordinated by the International Bureau for Epilepsy (IBE), an organisation comprising epilepsy associations from across the world, and the International League Against Epilepsy (ILAE), a global organisation representing healthcare professionals working in the field of epilepsy.

It is scheduled to be held each year on the second Monday in February, with plans to raise awareness of the condition across Europe.

UCB's campaign involves online video diaries made by people living with epilepsy. The company said the diaries provide an insight into modern perceptions of the condition, as well as what epilepsy is like to live with.

People involved in the series of videos include Marion, who won an Olympic silver medal in cycling for France in 2000, and Julie and David, whose 11-year-old son Dominic has severe epilepsy.

UCB has launched 'Epilepsy In Our Time'


Commenting on the 'Epilepsy In Our Time' campaign, Mike Glynn, president, IBE, said: "Epilepsy is the most common serious brain disorder, affecting 6 million people in Europe, but is an under-recognised and poorly understood condition, often leaving individuals exposed to stigma and prejudice. We welcome any new initiative that raises awareness and understanding of epilepsy."

European Epilepsy Day follows the annual Latin American Epilepsy Day held on September 9, with the IBE saying it plans to hold an annual day in each of its seven regions.

Plans for an international epilepsy day have been postponed until the World Health Organization is able to offer its support, according to the IBE.

Belgium-based biopharma UCB specialises in developing therapies for severe central nervous system or immunological disorders, and has several epilepsy drugs approved for marketing, including Vimpat (lacosamide) and Keppra (levetiracetam).

14th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Infographics